UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The effects of dose and timing of esomeprazole administration on 24‐h, daytime and night‐time acid inhibition in healthy volunteers

Alimentary pharmacology & therapeutics, 2010-11, Vol.32 (10), p.1249-1256

2010

Volltextzugriff (PDF)

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

Clinical pharmacokinetics, 2001, Vol.40 (6), p.411-426

2001

Volltextzugriff (PDF)

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects

European journal of clinical pharmacology, 2000-12, Vol.56 (9-10), p.665-670

2000

Volltextzugriff (PDF)

A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

European journal of clinical pharmacology, 2005, Vol.60 (11), p.779-784

2005

Volltextzugriff (PDF)

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

Alimentary pharmacology & therapeutics, 2010-08, Vol.32 (3), p.443-447

2010

Volltextzugriff (PDF)

Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole

Clinical pharmacokinetics, 2001, Vol.40 (7), p.523-537

2001

Volltextzugriff (PDF)

The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro‐oesophageal reflux disease

Alimentary pharmacology & therapeutics, 1998-01, Vol.12 (1), p.35-40

1998

Volltextzugriff (PDF)

Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

Alimentary pharmacology & therapeutics, 2000-07, Vol.14 (7), p.861-867

2000

Volltextzugriff (PDF)

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

British journal of clinical pharmacology, 1998-04, Vol.45 (4), p.369-375

1998

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole

Alimentary pharmacology & therapeutics, 2001-10, Vol.15 (10), p.1563-1569

2001

Volltextzugriff (PDF)

Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study

Alimentary pharmacology & therapeutics, 2004-11, Vol.20 (10), p.1099-1104

2004

Volltextzugriff (PDF)

Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects

International journal of clinical pharmacology and therapeutics, 2007-06, Vol.45 (6), p.345-354

2007

Volltextzugriff (PDF)

Pharmacokinetic study of Esomeprazole in the elderly

Clinical pharmacokinetics, 2001, Vol.40 (2), p.145-150

2001

Volltextzugriff (PDF)

Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects

International journal of clinical pharmacology and therapeutics, 2006-03, Vol.44 (3), p.119-127

2006

Volltextzugriff (PDF)

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

European journal of clinical pharmacology, 2004-10, Vol.60 (8), p.531-539

2004

Volltextzugriff (PDF)

Esomeprazole 20 mg administered as a 30-minute infusion provides a similar level of acid control as oral administration in healthy subjects

The American journal of gastroenterology, 2003-09, Vol.98 (s9), p.S21-S21

2003

Volltextzugriff (PDF)

Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intragastric Acidity in Healthy Subjects

Scandinavian journal of gastroenterology, 1993, Vol.28 (2), p.179-184

1993

Volltextzugriff (PDF)

Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction

Clinical pharmacokinetics, 2002, Vol.41 (12), p.999-1004

2002

Volltextzugriff (PDF)

Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH-metry study with omeprazole

European journal of gastroenterology & hepatology, 1998-07, Vol.10 (7), p.601-606

1998

Volltextzugriff (PDF)

ESOMEPRAZOLE 40 MG INTRAVENOUS PROVIDES FASTER AND MORE EFFECTIVE ACID CONTROL THAN PANTOPRAZOLE 40 MG INTRAVENOUS AFTER FIRST DOSE AND 5 DAYS: 70

The American journal of gastroenterology, 2003-09, Vol.98, p.S24-S25

2003

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients

Canadian journal of gastroenterology, 1997-11, Vol.11 (8), p.657-660

1997

Volltextzugriff (PDF)

Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response

Journal of pediatric gastroenterology and nutrition, 2017-09, Vol.65 (3), p.272-277

2017

Volltextzugriff (PDF)

Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients

Digestion, 1992, Vol.53 (3-4), p.171-178

1992

Volltextzugriff (PDF)

Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies

European journal of gastroenterology & hepatology, 2005-02, Vol.17 (2), p.191-197

2005

Volltextzugriff (PDF)

Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man

Gut, 1988-01, Vol.29 (1), p.75-80

1988

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Humans
(31)
Male
(29)
Adult
(26)
Biological And Medical Sciences
(26)
Medical Sciences
(26)
Female
(24)
Pharmacology. Drug Treatments
(24)
Digestive System
(20)
Pharmacology & Pharmacy
(19)
Gastroenterology & Hepatology
(18)
Middle Aged
(17)
Cross-Over Studies
(15)
Esomeprazole
(15)
Administration, Oral
(12)
Anti-Ulcer Agents - Administration & Dosage
(12)
Omeprazole - Administration & Dosage
(12)
Anti-Ulcer Agents - Pharmacokinetics
(11)
Omeprazole - Pharmacokinetics
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The effects of dose and timing of esomeprazole administration on 24‐h, daytime and night‐time acid inhibition in healthy volunteers

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects

A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?

Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole

The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro‐oesophageal reflux disease

Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole

Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study

Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects

Pharmacokinetic study of Esomeprazole in the elderly

Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

Esomeprazole 20 mg administered as a 30-minute infusion provides a similar level of acid control as oral administration in healthy subjects

Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intragastric Acidity in Healthy Subjects

Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction

Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH-metry study with omeprazole

ESOMEPRAZOLE 40 MG INTRAVENOUS PROVIDES FASTER AND MORE EFFECTIVE ACID CONTROL THAN PANTOPRAZOLE 40 MG INTRAVENOUS AFTER FIRST DOSE AND 5 DAYS: 70

Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients

Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response

Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients

Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies

Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man

Suchergebnisse filtern